Epithelial–Mesenchymal Transition Suppresses AMPK and Sensitizes Cancer Cells to Pyroptosis under Energy Stress
暂无分享,去创建一个
Shuang Huang | B. Law | M. Tan | T. Xiao | Lizi Wu | Jennifer W. Li | Jianrong Lu | Huacheng Luo | Mingwei Liang | Anitha K Shenoy | Jia Chang | Sarah Lulu | Ozlem Calbay | Hao Chen
[1] Bingshu E. Chen,et al. Effect of Metformin vs Placebo on Invasive Disease-Free Survival in Patients With Breast Cancer: The MA.32 Randomized Clinical Trial. , 2022, JAMA.
[2] G. Christofori,et al. Distinct contributions of partial and full EMT to breast cancer malignancy. , 2021, Developmental cell.
[3] Masafumi Takahashi,et al. Loop Between NLRP3 Inflammasome and Reactive Oxygen Species. , 2021, Antioxidants & redox signaling.
[4] John G Doench,et al. Control of gasdermin D oligomerization and pyroptosis by the Ragulator-Rag-mTORC1 pathway , 2021, Cell.
[5] S. Cai,et al. Metformin Adjunct With Antineoplastic Agents for the Treatment of Lung Cancer: A Meta-Analysis of Randomized Controlled Trials and Observational Cohort Studies , 2021, Frontiers in Pharmacology.
[6] Beth K. Martin,et al. Single-cell lineage tracing of metastatic cancer reveals selection of hybrid EMT states. , 2021, Cancer cell.
[7] N. Matsumura,et al. Tumor Immune Microenvironment during Epithelial–Mesenchymal Transition , 2021, Clinical Cancer Research.
[8] D. Hardie,et al. AMP-Activated Protein Kinase: Do We Need Activators or Inhibitors to Treat or Prevent Cancer? , 2020, International journal of molecular sciences.
[9] A. Strasser,et al. Emerging connectivity of programmed cell death pathways and its physiological implications , 2020, Nature Reviews Molecular Cell Biology.
[10] Tao Yu,et al. NLRP3 inflammasome in endothelial dysfunction , 2020, Cell Death & Disease.
[11] B. Vanderhyden,et al. Context specificity of the EMT transcriptional response , 2020, Nature Communications.
[12] Kristen Fousek,et al. Tumor Plasticity and Resistance to Immunotherapy. , 2020, Trends in cancer.
[13] J. Lieberman,et al. FDA-approved disulfiram inhibits pyroptosis by blocking gasdermin D pore formation , 2020, Nature Immunology.
[14] Z. Xiao,et al. Transcriptional suppression of AMPKα1 promotes breast cancer metastasis upon oncogene activation , 2020, Proceedings of the National Academy of Sciences.
[15] Y. Ruan,et al. LATS kinase–mediated CTCF phosphorylation and selective loss of genomic binding , 2020, Science Advances.
[16] Hao Wu,et al. TRPM2, linking oxidative stress and Ca2+ permeation to NLRP3 inflammasome activation. , 2020, Current opinion in immunology.
[17] Jitendra Kumar Meena,et al. Energy stress-mediated AMPK activation inhibits ferroptosis , 2020, Nature Cell Biology.
[18] A. Jaśkiewicz,et al. 2-Deoxy-d-Glucose and Its Analogs: From Diagnostic to Therapeutic Agents , 2019, International journal of molecular sciences.
[19] D. Cescon,et al. A phase II randomized clinical trial of the effect of metformin versus placebo on progression-free survival in women with metastatic breast cancer receiving standard chemotherapy. , 2019, Breast.
[20] F. Shao,et al. The gasdermins, a protein family executing cell death and inflammation , 2019, Nature Reviews Immunology.
[21] Arnaud J. Legrand,et al. The Diversification of Cell Death and Immunity: Memento Mori. , 2019, Molecular cell.
[22] Luca Mazzarella,et al. Combination of Hypoglycemia and Metformin Impairs Tumor Metabolic Plasticity and Growth by Modulating the PP2A-GSK3β-MCL-1 Axis. , 2019, Cancer cell.
[23] Han-Ming Shen,et al. Critical role of AMPK in redox regulation under glucose starvation , 2019, Redox biology.
[24] P. Gutin,et al. Gboxin is an oxidative phosphorylation inhibitor that targets glioblastoma , 2019, Nature.
[25] Y. Ishikawa,et al. Epithelial-to-Mesenchymal Transition Is a Mechanism of ALK Inhibitor Resistance in Lung Cancer Independent of ALK Mutation Status. , 2019, Cancer research.
[26] Piyush B. Gupta,et al. Phenotypic Plasticity: Driver of Cancer Initiation, Progression, and Therapy Resistance. , 2019, Cell stem cell.
[27] T. Brabletz,et al. Non-redundant functions of EMT transcription factors , 2019, Nature Cell Biology.
[28] X. Fang,et al. Ovarian Cancer Relies on Glucose Transporter 1 to Fuel Glycolysis and Growth: Anti-Tumor Activity of BAY-876 , 2018, Cancers.
[29] O. Nanni,et al. Metformin plus chemotherapy versus chemotherapy alone in the first-line treatment of HER2-negative metastatic breast cancer. The MYME randomized, phase 2 clinical trial , 2018, Breast Cancer Research and Treatment.
[30] M. Protopopova,et al. An inhibitor of oxidative phosphorylation exploits cancer vulnerability , 2018, Nature Medicine.
[31] Johan Hartman,et al. Chemoresistance Evolution in Triple-Negative Breast Cancer Delineated by Single-Cell Sequencing , 2018, Cell.
[32] T. Voet,et al. Identification of the tumour transition states occurring during EMT , 2018, Nature.
[33] P. Agostinis,et al. Cell death and immunity in cancer: From danger signals to mimicry of pathogen defense responses , 2017, Immunological reviews.
[34] Wen Bu,et al. Breast tumor cell-specific knockout of Twist1 inhibits cancer cell plasticity, dissemination, and lung metastasis in mice , 2017, Proceedings of the National Academy of Sciences.
[35] S. Zhang,et al. A randomized phase II study of aromatase inhibitors plus metformin in pre-treated postmenopausal patients with hormone receptor positive metastatic breast cancer , 2017, Oncotarget.
[36] Jill P. Mesirov,et al. Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway , 2017, Nature.
[37] Stuart L. Schreiber,et al. Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition , 2017, Nature.
[38] R. Shaw,et al. AMPK: Mechanisms of Cellular Energy Sensing and Restoration of Metabolic Balance. , 2017, Molecular cell.
[39] C. Pilarsky,et al. The EMT-activator Zeb1 is a key factor for cell plasticity and promotes metastasis in pancreatic cancer , 2017, Nature Cell Biology.
[40] D. Bachovchin,et al. Pyroptosis and Apoptosis Pathways Engage in Bidirectional Crosstalk in Monocytes and Macrophages. , 2017, Cell chemical biology.
[41] Matthew L. Albert,et al. Dying cells actively regulate adaptive immune responses , 2017, Nature Reviews Immunology.
[42] L. Chin,et al. Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer , 2017, Nature.
[43] Binbin Xie,et al. Glucose transporter GLUT1 expression and clinical outcome in solid tumors: a systematic review and meta-analysis , 2017, Oncotarget.
[44] Lung-Ji Chang,et al. Epithelial-to-mesenchymal transition confers pericyte properties on cancer cells. , 2016, The Journal of clinical investigation.
[45] T. Müller,et al. Identification and Optimization of the First Highly Selective GLUT1 Inhibitor BAY‐876 , 2016, ChemMedChem.
[46] G. Stassi,et al. Epithelial–mesenchymal transition: a new target in anticancer drug discovery , 2016, Nature Reviews Drug Discovery.
[47] A. Brunet,et al. AMPK: An Energy-Sensing Pathway with Multiple Inputs and Outputs. , 2016, Trends in cell biology.
[48] Jean Paul Thiery,et al. EMT: 2016 , 2016, Cell.
[49] Roberto Bianco,et al. Mechanisms of lapatinib resistance in HER2-driven breast cancer. , 2015, Cancer treatment reviews.
[50] Stephen T. C. Wong,et al. EMT is not required for lung metastasis but contributes to chemoresistance , 2015, Nature.
[51] V. LeBleu,et al. EMT Program is Dispensable for Metastasis but Induces Chemoresistance in Pancreatic Cancer , 2015, Nature.
[52] R. Chapple,et al. AMPK Protects Leukemia-Initiating Cells in Myeloid Leukemias from Metabolic Stress in the Bone Marrow. , 2015, Cell stem cell.
[53] R. Weinberg,et al. Distinct EMT programs control normal mammary stem cells and tumour-initiating cells , 2015, Nature.
[54] Michael J. Ziller,et al. Transcription factor binding dynamics during human ESC differentiation , 2015, Nature.
[55] A. Morris,et al. Metformin in cancer treatment and prevention. , 2015, Annual review of medicine.
[56] B. Viollet,et al. Metformin: from mechanisms of action to therapies. , 2014, Cell metabolism.
[57] Ying Wang,et al. SNAI2 Controls the Undifferentiated State of Human Epidermal Progenitor Cells , 2014, Stem cells.
[58] G. Longmore,et al. Transient SNAIL1 expression is necessary for metastatic competence in breast cancer. , 2014, Cancer research.
[59] Lorenzo Galluzzi,et al. Metabolic control of cell death , 2014, Science.
[60] V. Natarajan,et al. Reactive oxygen species at the crossroads of inflammasome and inflammation , 2014, Front. Physiol..
[61] Samy Lamouille,et al. Molecular mechanisms of epithelial–mesenchymal transition , 2014, Nature Reviews Molecular Cell Biology.
[62] Jan Budczies,et al. Online Survival Analysis Software to Assess the Prognostic Value of Biomarkers Using Transcriptomic Data in Non-Small-Cell Lung Cancer , 2013, PloS one.
[63] G. Mills,et al. AMPK: a contextual oncogene or tumor suppressor? , 2013, Cancer research.
[64] Liu Wei,et al. LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin. , 2013, Cancer cell.
[65] B. Law,et al. An in vivo model of epithelial to mesenchymal transition reveals a mitogenic switch. , 2012, Cancer letters.
[66] Jing Yang,et al. Spatiotemporal regulation of epithelial-mesenchymal transition is essential for squamous cell carcinoma metastasis. , 2012, Cancer cell.
[67] Michael Peyton,et al. An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance , 2012, Clinical Cancer Research.
[68] C. Thornton,et al. AMP-activated protein kinase: new regulation, new roles? , 2012, The Biochemical journal.
[69] Jae Cheol Lee,et al. Activation of the AXL Kinase Causes Resistance to EGFR-Targeted Therapy in Lung Cancer , 2012, Nature Genetics.
[70] Navdeep S. Chandel,et al. AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress , 2012, Nature.
[71] M. R. Lamprecht,et al. Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death , 2012, Cell.
[72] D. Hardie,et al. AMPK: a nutrient and energy sensor that maintains energy homeostasis , 2012, Nature Reviews Molecular Cell Biology.
[73] Jennifer B Dennison,et al. Dual Inhibition of Tumor Energy Pathway by 2-Deoxyglucose and Metformin Is Effective against a Broad Spectrum of Preclinical Cancer Models , 2011, Molecular Cancer Therapeutics.
[74] C. Lee,et al. Clinical and molecular evidences of epithelial to mesenchymal transition in acquired resistance to EGFR-TKIs. , 2011, Lung cancer.
[75] S. Digumarthy,et al. Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors , 2011, Science Translational Medicine.
[76] T. Oyama,et al. Epithelial-mesenchymal transition in EGFR-TKI acquired resistant lung adenocarcinoma. , 2010, Anticancer research.
[77] C. Bertolotto,et al. Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells. , 2010, Cancer research.
[78] Jeffrey M. Rosen,et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features , 2009, Proceedings of the National Academy of Sciences.
[79] A. Look,et al. Slug Antagonizes p53-Mediated Apoptosis of Hematopoietic Progenitors by Repressing puma , 2005, Cell.
[80] R. Sabirov,et al. Cells die with increased cytosolic ATP during apoptosis: a bioluminescence study with intracellular luciferase , 2005, Cell Death and Differentiation.
[81] Robert D Cardiff,et al. The transcriptional repressor Snail promotes mammary tumor recurrence. , 2005, Cancer cell.
[82] H. Moses,et al. Induction by transforming growth factor-β1 of epithelial to mesenchymal transition is a rare event in vitro , 2004, Breast Cancer Research.
[83] M. Owen,et al. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. , 2000, The Biochemical journal.
[84] M. Rigoulet,et al. Dimethylbiguanide Inhibits Cell Respiration via an Indirect Effect Targeted on the Respiratory Chain Complex I* , 2000, The Journal of Biological Chemistry.
[85] Y. Tsujimoto,et al. ATP-dependent steps in apoptotic signal transduction. , 1999, Cancer research.
[86] Y. Tsujimoto,et al. Intracellular ATP levels determine cell death fate by apoptosis or necrosis. , 1997, Cancer research.